Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top

ESMO 2025: The evERA trial

Dr. Erica Mayer highlights the benefit of treatment with giredestrant plus everolimus in patients with ER-positive, HER2-negative advanced breast cancer who have previously received a CDK4/6 inhibitor. 

More from ESMO Congress 2025

TIGIT and PD-1 blockade encouraging in gastroesophageal cancer

Novel T-cell therapy shows promise in uveal melanoma

ESMO 2025: The evERA trial

ESMO 2025: The KEYNOTE-905 trial

ESMO 2025: The DYNAMIC-III trial

ctDNA-guided adjuvant atezolizumab improves MIBC survival

POTOMAC supports add-on durvalumab for high-risk NMIBC

Targeted agents show first-line potential in HER2-mutant NSCLC

Adding immunotherapy improves survival in ovarian cancer

PSMAddition shows PFS gain with 177Lu-PSMA-617 in mHSPC

Ivonescimab plus chemo could be new option for squamous NSCLC

Bispecific CAR T-cell therapy promising in R/R DLBCL

Real-world data confirm effectiveness of radium-223

PFS benefit of gedatolisib for advanced breast cancer shown

Tumor-infiltrating clonal hematopoiesis may be a target for cancer treatment

First-line sacituzumab govitecan improves PFS in metastatic TNBC

No success for ctDNA-guided de-escalation in colon cancer

Datopotamab deruxtecan effective in TNBC

Image Credits
Erica Mayer/© Springer Medicine, Woman receiving an intravenous infusion/© FatCamera / Getty Images / iStock (symbolic image with model), Christof Vulsteke/© Springer Medicine, Jeanne Tie/© Springer Medicine, DNA testing of blood - conceptual/© blindturtle / stock.adobe.com